Anti-CD20 monoclonal antibody causing B-cell depletion via ADCC, CDC, and apoptosis.
Chimeric anti-CD20 monoclonal IgG1 that binds CD20 on B cells and mediates B-cell depletion via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and induction of apoptosis.
YES
DIRECT
Rituximab binds CD20 on B cells and induces killing via Fc-mediated ADCC (NK cells/macrophages), complement-dependent cytotoxicity, and direct apoptosis upon crosslinking.
Full-length bispecific monoclonal antibody that binds CD20 on B cells and CD3 on T cells to redirect and activate cytotoxic T-cell killing of malignant B cells.
Full-length bispecific monoclonal antibody that binds CD20 on B cells and CD3 on T cells, cross-linking T cells to CD20+ malignant B cells to activate T-cell receptor signaling and redirect cytotoxic T-cell killing of the tumor cells.
YES
DIRECT
Odronextamab crosslinks CD3 on T cells with CD20 on target cells, activating T cells to kill CD20+ cells via redirected cytotoxicity (perforin/granzyme-mediated apoptosis).
Autologous tumor-infiltrating lymphocyte (TIL) adoptive cell therapy administered intravenously after lymphodepleting chemotherapy to mediate TCR-dependent cytotoxicity against tumor cells.
Autologous TILs expanded ex vivo are reinfused after lymphodepleting chemotherapy. They recognize patient-specific tumor antigens via TCR-MHC and kill tumor cells through perforin/granzyme-mediated cytotoxicity and cytokine release, with IL-2 supporting T-cell activation, proliferation, and persistence.
YES
DIRECT
Adoptively transferred TILs recognize tumor-associated peptides presented on HLA-A/B/C via their TCR and kill target cells through perforin/granzyme-mediated cytolysis and Fas–FasL apoptosis, with IL-2 supporting T-cell function.
Full-length bispecific monoclonal antibody that binds CD20 on B cells and CD3 on T cells to redirect and activate cytotoxic T-cell killing of malignant B cells.
Full-length bispecific monoclonal antibody that binds CD20 on B cells and CD3 on T cells, cross-linking T cells to CD20+ malignant B cells to activate T-cell receptor signaling and redirect cytotoxic T-cell killing of the tumor cells.
NO
INDIRECT
Binds CD3 on T cells to activate and redirect them to kill CD20+ B cells (perforin/granzyme-mediated cytotoxicity); CD3+ cells are engaged, not targeted for killing.
Anti-CD20 monoclonal antibody that depletes B cells via complement-dependent cytotoxicity, ADCC, and apoptosis.
Chimeric anti‑CD20 monoclonal antibody that binds CD20 on pre‑B and mature B cells, leading to B‑cell depletion primarily via complement‑dependent cytotoxicity (CDC), antibody‑dependent cellular cytotoxicity (ADCC) and phagocytosis, and induction of apoptosis of CD20‑positive cells.
YES
DIRECT
Anti‑CD20 antibody binding triggers complement-mediated lysis (CDC) and Fc receptor–mediated ADCC/phagocytosis by immune effector cells; can also induce apoptosis of CD20+ cells.